T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overcoming immune escape. Here, we identify a myeloid-intrinsic mechanism governed by the NF-κB effector molecule GADD45b that restricts tumor-associated inflammation and T-cell trafficking into tumors. In various models of solid cancers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of proinflammatory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing oncogenesis. Our results provide a basis to interpret clinical evidence that elevated expression of GADD45B confers poorclinical outcomes in most human cancers. Furthermore, they suggest a therapeutic target in GADD45β for reprogramming TAM to overcome immunosuppression and T-cell exclusion from the TME.

GADD45β loss ablates innate immunosuppression in cancer / D. Verzella, J. Bennett, M. Fischietti, A.K. Thotakura, C. Recordati, F. Pasqualini, D. Capece, D. Vecchiotti, D. D'Andrea, B. Di Francesco, M.D. Maglie, F. Begalli, L. Tornatore, S. Papa, T. Lawrence, S.J. Forbes, A. Sica, E. Alesse, F. Zazzeroni, G. Franzoso. - In: CANCER RESEARCH. - ISSN 0008-5472. - 78:5(2018 Mar 01), pp. 1275-1292.

GADD45β loss ablates innate immunosuppression in cancer

C. Recordati;
2018

Abstract

T-cell exclusion from the tumor microenvironment (TME) is a major barrier to overcoming immune escape. Here, we identify a myeloid-intrinsic mechanism governed by the NF-κB effector molecule GADD45b that restricts tumor-associated inflammation and T-cell trafficking into tumors. In various models of solid cancers refractory to immunotherapies, including hepatocellular carcinoma and ovarian adenocarcinoma, Gadd45b inhibition in myeloid cells restored activation of proinflammatory tumor-associated macrophages (TAM) and intratumoral immune infiltration, thereby diminishing oncogenesis. Our results provide a basis to interpret clinical evidence that elevated expression of GADD45B confers poorclinical outcomes in most human cancers. Furthermore, they suggest a therapeutic target in GADD45β for reprogramming TAM to overcome immunosuppression and T-cell exclusion from the TME.
English
Animals; Antigens, Differentiation; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Female; Humans; Immune Tolerance; Liver Neoplasms; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells; Neoplasms; T-Lymphocytes; Tumor Cells, Cultured; Tumor Microenvironment; Immunosuppression
Settore VET/03 - Patologia Generale e Anatomia Patologica Veterinaria
Articolo
Esperti anonimi
Pubblicazione scientifica
1-mar-2018
American Association for Cancer Research
78
5
1275
1292
18
Pubblicato
Periodico con rilevanza internazionale
Aderisco
info:eu-repo/semantics/article
GADD45β loss ablates innate immunosuppression in cancer / D. Verzella, J. Bennett, M. Fischietti, A.K. Thotakura, C. Recordati, F. Pasqualini, D. Capece, D. Vecchiotti, D. D'Andrea, B. Di Francesco, M.D. Maglie, F. Begalli, L. Tornatore, S. Papa, T. Lawrence, S.J. Forbes, A. Sica, E. Alesse, F. Zazzeroni, G. Franzoso. - In: CANCER RESEARCH. - ISSN 0008-5472. - 78:5(2018 Mar 01), pp. 1275-1292.
open
Prodotti della ricerca::01 - Articolo su periodico
20
262
Article (author)
si
D. Verzella, J. Bennett, M. Fischietti, A.K. Thotakura, C. Recordati, F. Pasqualini, D. Capece, D. Vecchiotti, D. D'Andrea, B. Di Francesco, M.D. Magl...espandi
File in questo prodotto:
File Dimensione Formato  
1275.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.5 MB
Formato Adobe PDF
2.5 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/658194
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 33
  • OpenAlex ND
social impact